MLTX
Price
$10.82
Change
+$0.24 (+2.27%)
Updated
Oct 9 closing price
Capitalization
983.83M
37 days until earnings call
Intraday BUY SELL Signals
XNCR
Price
$24.63
Change
+$0.13 (+0.53%)
Updated
Oct 9 closing price
Capitalization
1.9B
29 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MLTX vs XNCR

MLTX vs XNCR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MLTX vs. XNCR commentary
Oct 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLTX is a Hold and XNCR is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
MLTX vs XNCR: Fundamental Ratings
MLTX
XNCR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
88
Overvalued
PROFIT vs RISK RATING
1..100
98100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
6535
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
4485

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MLTX's Valuation (24) in the null industry is somewhat better than the same rating for XNCR (88) in the Biotechnology industry. This means that MLTX’s stock grew somewhat faster than XNCR’s over the last 12 months.

MLTX's Profit vs Risk Rating (98) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that MLTX’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as MLTX (98) in the null industry. This means that XNCR’s stock grew similarly to MLTX’s over the last 12 months.

XNCR's Price Growth Rating (35) in the Biotechnology industry is in the same range as MLTX (65) in the null industry. This means that XNCR’s stock grew similarly to MLTX’s over the last 12 months.

XNCR's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for MLTX (100) in the null industry. This means that XNCR’s stock grew significantly faster than MLTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MLTXXNCR
RSI
ODDS (%)
Bullish Trend 3 days ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
79%
Momentum
ODDS (%)
N/A
Bullish Trend 3 days ago
70%
MACD
ODDS (%)
Bullish Trend 3 days ago
79%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 20 days ago
84%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 5 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
84%
COMPARISON
Comparison
Oct 11, 2026
Stock price -- (MLTX: $10.82 vs. XNCR: $24.63)
Brand notoriety: MLTX and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLTX: 110% vs. XNCR: 69%
Market capitalization -- MLTX: $983.83M vs. XNCR: $1.9B
MLTX [@Biotechnology] is valued at $983.83M. XNCR’s [@Biotechnology] market capitalization is $1.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLTX’s FA Score shows that 1 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).

  • MLTX’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, XNCR is a better buy in the long-term than MLTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLTX’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 2 bullish TA indicator(s).

  • MLTX’s TA Score: 5 bullish, 3 bearish.
  • XNCR’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, MLTX is a better buy in the short-term than XNCR.

Price Growth

MLTX (@Biotechnology) experienced а -5.17% price change this week, while XNCR (@Biotechnology) price change was -0.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.51%. For the same industry, the average monthly price growth was -13.43%, and the average quarterly price growth was -4.26%.

Reported Earning Dates

MLTX is expected to report earnings on Nov 17, 2026.

XNCR is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-2.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.